Menu
1 min read · estimated
APPROVED USE
What FDA approved
Single-agent treatment of advanced or metastatic breast cancer when anthracycline- or taxane-containing chemotherapy is unsuitable.
LAMPGEN ANALYSIS
Why it matters
This revision clarifies the monotherapy population and accompanies updated dosing options.
What research teams should watch
Record why an anthracycline or taxane is unsuitable and document the selected starting dose and follow-up.
PRIMARY RECORDS